Exelixis
EXEL
#1694
Rank
S$15.47 B
Marketcap
S$57.49
Share price
-0.02%
Change (1 day)
19.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2025 (TTM): S$1.14 Billion

According to Exelixis's latest financial reports the company's current earnings are S$2.28 Billion. In 2024 the company made an earning of S$0.88 Billion, an increase over its 2023 earnings that were of S$0.33 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) S$1.14 B29.72%
2024 S$0.88 B164.69%
2023 S$0.33 B9.89%
2022 S$0.30 B-20.33%
2021 S$0.38 B124.82%
2020 S$0.16 B-67.14%
2019 S$0.51 B-11.94%
2018 S$0.58 B185.09%
2017 S$0.20 B-325.82%
2016 -S$91.01 Million-58.12%
2015 -S$0.22 Billion-37.61%
2014 -S$0.35 Billion9.75%
2013 -S$0.32 Billion65.96%
2012 -S$0.2 Billion-291.63%
2011 S$99.77 M-195.59%
2010 -S$0.11 Billion-42.17%
2009 -S$0.19 Billion-18.98%
2008 -S$0.23 Billion-6.99%
2007 -S$0.24 Billion46.3%
2006 -S$0.17 Billion33.25%
2005 -S$0.13 Billion-30.92%
2004 -S$0.18 Billion44.29%
2003 -S$0.13 Billion12.86%
2002 -S$0.11 Billion22.79%
2001 -S$88.96 Million60.14%
2000 -S$55.55 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
S$12.08 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
S$11.79 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$29.92 B 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$10.40 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$10.68 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
S$41.98 B 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$15.35 B 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-S$42.2 Million-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-S$37.64 Million-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA